November 9, 2023 10:53 AM EST
Deals
R&D

Re­cur­sion and Bay­er to wind down fi­bro­sis R&D pact af­ter three years, re­fo­cus­ing on can­cer

Andrew Dunn

Senior Biopharma Correspondent

Re­cur­sion Phar­ma­ceu­ti­cals and Bay­er re­worked a re­search pact to fo­cus on on­col­o­gy in­stead of fi­bro­sis as the Ger­man drug­mak­ing gi­ant homes in on can­cer un­der …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times